NEWS.
Exciting news for the AML community: The FDA has expanded approval of revumenib, a first-in-class oral menin inhibitor, to include adults and children with relapsed or refractory acute myeloid leukemia harboring NPM1 mutations. Originally approved in 2024 for KMT2A-rearranged AML, this expanded indication is particularly significant because NPM1 mutations are far more common than KMT2A alterations. With this approval, revumenib becomes a treatment option for up to 40% of AML patients—a substantial advancement in precision medicine for this aggressive disease.
I am deeply grateful and honored to have contributed to this journey by demonstrating therapeutic efficacy in preclinical models and exploring the mechanism of action of menin inhibitors, work that was published in Science (2020) and Cancer Discovery (2023).
Witnessing a compound progress from the lab bench to an FDA-approved therapy that is now helping patients in the clinic is one of the most exciting and motivating experiences of my scientific career. It exemplifies the power of translational research and reinforces why we do this work. This milestone inspires our lab to continue pushing forward in our mission to identify novel therapeutic vulnerabilities in AML.
Menin Inhibitor - Revumenib - has been FDA approved for NPM1c AML patients
TSURUOKA CONFERENCE 2025
EPIGENETICS, HEMATOPOIESIS & CANCER
I was honored to attend an inspiring meeting in Japan hosted by Professor Akihito Yokoyama. This exceptional gathering united many Armstrong Lab alumni alongside leading scientists whose groundbreaking work on epigenetics and leukemia - particularly Menin-MLL and NUP98-fusion AML - has profoundly influenced our field over the past decades. Their research has been instrumental in shaping the questions we investigate in our own laboratory. I am deeply grateful to Professor Yokoyama for his hospitality and this valuable opportunity to connect with colleagues whose contributions continue to be fundamental to the our work in the lab.
UCT Science Day, Frankfurt 2025
with posters by
Arezo, Hannah & Marcel
The ERC Starting Grants are among the most highly regarded and competitive research grants for young research group leaders in Europe. This year 494 researchers across different disciplines were selected out of 3,474 proposals.
Dr. Hannah Uckelmann is among this years awardees is for her project “EpiTransformers”, which aims to explore the epigenetic processes responsible for driving the development of leukemia. Her ERC project specifically investigates components of the nuclear export machinery that are hijacked by cancer cells to drive oncogenic gene expression programs. The ultimate goal of Dr. Uckelmanns research is to elucidate the chromatin complexes that are essential to leukemia cells and thereby improve our understanding of disease biology.
2024 ERC Starting Grant!
Rhein-Main Cancer Retreat 2024
Posters by Sara, Arezo and Hannah!
Frankfurt Cancer Conference, 2024
EHA Meeting 2024
Madrid, 2024
Hannah was accepted to join the EHA-ASH Translational Research Training in Hematology
TRTH is a year-long training and mentoring program for early career researchers transitioning to independence.
Find out more:
https://ehaweb.org/research/research-trainings/eha-ash-translational-research-training-in-hematology/
Hannah travels to Japan to give the keynote in Kumamoto for the 21st IRCMS Symposium on The Dynamics and Development of Normal and Malignant Hematopoietic Stem Cells on Feb. 20-21, 2024. Thank you Goro Sashida for the invitation!
Hannah receives Max-Eder Junior Research Group funding!
The Uckelmann lab receives highly competitive junior research group funding from the German Cancer Aid (Deutsche Krebshilfe). Her Max-Eder group will explore the epigenetic network of mutant NPM1 in acute myeloid leukemia.
Find out more:
Uckelmann lab receives 2023 Discovery & Development Grant!
EHA Bilateral Collaborative Grant 2025
At the 2025 EHA congress in Milan the Uckelmann Lab was awarded a Collaborative Research grant together with their collaborators from Lorenzo Brunetti’s laboratory at the University of Ancona. We are excited to embark on this European joint venture to explore the therapeutic and epigenetic effects of XPO1-inhibitors in NPM1c AML patients from ongoing clinical trials.